| Study |
Exclusion reasons |
Rmk |
Reference |
|
Ephross (all treated), 2014
|
inadequate or absent control group
|
PV registry of GlaxoSmithKline.
|
Ephross SA Headache 2014;54:1158-72 10.1111/head.12375
|
|
Yusuf (all treated), 2018
|
inadequate or absent control group
|
This study was funded by Amgen and was conceived and conducted by Amgen employees.
|
Yusuf Pharmacoepidemiol Drug Saf 2018; 27:1309-1315 10.1002/pds.4658
|
|
Fiore (PV data - Rizatriptan only), 2005
|
inadequate or absent control group
|
|
Fiore Cephalalgia 2005; 25:685-8 10.1111/j.1468-2982.2004.00929.x
|
|
Wilton (no control group), 1998
|
inadequate or absent control group
|
|
Wilton Br J Obstet Gynaecol 1998; 105:882-9 10.1111/j.1471-0528.1998.tb10234.x
|
|
Illoh, 2018
|
other reason
|
|
Illoh Pharmacoepidemiol Drug Saf 2018; 27:604-611 10.1002/pds.4409
|
|
Harris, 2017
|
other reason
|
|
Harris BMC Pregnancy Childbirth 2017; 17:224 10.1186/s12884-017-1399-0
|
|
Banhidy, 2007
|
not relevant exposure
|
|
Banhidy Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 134:157-63 10.1016/j.ejogrb.2006.08.025
|
|
Cunnington, 2009
|
repeat population groups, duplicate reports (most recent study included)
|
|
Cunnington M Headache 2009;49:1414-22 10.1111/j.1526-4610.2009.01529.x
|
|
Nezvalova-Henriksen, 2010
|
repeat population groups, duplicate reports (most recent study included)
|
|
Nezvalova-Henriksen Headache 2010; 50:563-75 10.1111/j.1526-4610.2010.01619.x
|
|
Källén, 2003
|
repeat population groups, duplicate reports (most recent study included)
|
|
Källén Reprod Toxicol. 2003 May-Jun;17(3):255-61.
10.1016/S0890-6238(03)00012-1
|
|
Wood 2016c, 2016
|
same data already obtained by other studies
|
|
Wood ME BMJ Open 2016;6:e011971 10.1136/bmjopen-2016-011971
|
